![Modulators Of Dnm2 Expression Freier; Susan M. ; et al. [Ionis Pharmaceuticals, Inc.]](https://uspto.report/patent/app/20190241896/US20190241896A1-20190808-C00005.png)
Modulators Of Dnm2 Expression Freier; Susan M. ; et al. [Ionis Pharmaceuticals, Inc.]
U.S. Patent Application 20190241896 for Modulators Of Dnm2 Expression
Modulators Of Dnm2 Expression Freier; Susan M. ; et al. [Ionis Pharmaceuticals, Inc.]
US20070031844A1 - Functional and hyperfunctional siRNA - Google Patents
A DNM2 Centronuclear Myopathy Mutation Reveals a Link between Recycling Endosome Scission and Autophagy - ScienceDirect
Differential impact of ubiquitous and muscle dynamin 2 isoforms in muscle physiology and centronuclear myopathy
US20190241896A1 - Modulators of dnm2 expression - Google Patents
JCI Insight - Physiological impact and disease reversion for the severe form of centronuclear myopathy linked to dynamin
Dynamin 2 (DNM2) as Cause of, and Modifier for, Human Neuromuscular Disease
A DNM2 Centronuclear Myopathy Mutation Reveals a Link between Recycling Endosome Scission and Autophagy - ScienceDirect
PDF) Likelihood of Nonspecific Activity of Gapmer Antisense Oligonucleotides Is Associated with Relative Hybridization Free Energy
Dynamin 2 (DNM2) as Cause of, and Modifier for, Human Neuromuscular Disease
WO2019089692A1 - MODULATORS OF ENaC EXPRESSION - Google Patents
Ion mobility coupled to native mass spectrometry as a relevant tool to investigate extremely small ligand-induced conformational changes - Analyst (RSC Publishing)
SEC Filing Sarepta Therapeutics, Inc.
